ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Immunogen (IMGN) Misses Q3 EPS by 42c
November 3, 2017 6:37 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.61), $0.42 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $33.62 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
... More


